Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders
Author:
Affiliation:
1. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
Publisher
Informa UK Limited
Subject
Cancer Research,Oncology,Hematology
Link
https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1498490
Reference56 articles.
1. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
2. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Role of the ITAM-Bearing Receptors Expressed by Natural Killer Cells in Cancer;Frontiers in Immunology;2022-06-10
2. BMFPs, a versatile therapeutic tool for redirecting a preexisting Epstein-Barr virus antibody response toward defined target cells;Science Advances;2022-02-11
3. Late onset neutropenia after rituximab and obinutuzumab treatment – characteristics of a class-effect toxicity;Leukemia & Lymphoma;2021-07-21
4. Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs;Cancers;2021-05-20
5. Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology;Recent Patents on Anti-Cancer Drug Discovery;2020-12-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3